Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency

Heart failure occurs when the heart can't pump blood well, causing shortness of breath and tiredness. Milrinone and levosimendan are medications that help the heart pump better. This study looks at how safe and effective these drugs are for people with serious heart problems and kidney issues (when kidneys don’t work well).

To join, you need to be 18-80 years old, have heart failure with a Left Ventricular Ejection Fraction (LVEF) less than 50%, and agree with your doctor that you need these drugs. You cannot join if you have certain other heart conditions, recent surgeries, or severe liver or kidney problems. Pregnant or breastfeeding women are also not allowed.

• The study checks if milrinone or levosimendan is the better choice for you.
• Participants must meet specific health criteria and need doctor approval.
• Potential benefits include improved heart function, but risks are involved.

Participants will help researchers make a safety prediction model for these drugs, which can benefit future patients.